• Increase font size
  • Default font size
  • Decrease font size

FDA approves vaccine for 2009-2010 seasonal influenza

Print E-mail
Wednesday, 22 July 2009 03:52

The U.S. Food and Drug Administration monday announced that it has approved a vaccine for 2009-2010 seasonal influenza in the United States. The seasonal influenza vaccine will not protect against the 2009 H1N1 influenza virus that resulted in the declaration of a pandemic by the World Health Organization (WHO) on June 11, 2009.

The FDA continues to work with manufacturers, international partners and other government agencies to facilitate the availability of a safe and effective vaccine against the 2009 H1N1 influenza virus.

Although this year’s seasonal vaccine is directed against other strains of influenza expected to be circulating and will not provide protection against the 2009 H1N1 influenza virus, it is still important for those Americans for whom it is recommended to receive the seasonal influenza vaccine. No vaccine is 100 percent effective against preventing disease, but vaccination is the best protection against influenza and can prevent many illnesses and deaths.

The six vaccine brand names and manufacturers are:

Afluria, CSL Limited (ASX:CSL)

Fluarix, GlaxoSmithKline (NYSE:GSK)

FluLaval, ID Biomedical Corporation

Fluvirin, Novartis AG (NYSE:NVS) and Diagnostics Limited

Fluzone, Sanofi Pasteur Inc.- Division of Sanofi-Aventis SA (EPA:SAN)

and FluMist, MedImmune Vaccines Inc.(UK-based pharmaceutical giant AstraZeneca acquired MedImmune in 2007.)

The vaccine for the 2009-2010 seasonal influenza contains: an A/Brisbane/59/2007 (H1N1)-like virus;

an A/Brisbane/10/2007 (H3N2)-like virus;

a B/Brisbane/60/2008-like virus.

Visit the FDA Web Page on Influenza Vaccine Safety & Availability. Read the FDA release for more info.




BiomedReports is not paid or compensated to report news and developments about publicly traded companies. Full disclosure can be read in the About Us Section

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus
 
about 13 hours ago FDA panel votes against Xgeva; Nervous GlaxoSmithKline Pulls Cash Out of Eurozone: Below is a look at some of th... http://t.co/h6kQSAz6
about 1 day ago Illumina’s Board Unanimously Rejects Roche’s Offer; Shire Announces FDA Approval of Vyvanse®: Below is a look at... http://t.co/L3FZivQV
about 1 day ago Achillion ($ACHN) hammered after BofA rates to "Underperform" citing no M&A speculation. What we said last month: http://t.co/usWk95O6
about 2 days ago Medgenics ($MDGN) up 10% on Monday! We first told you about the firm last Friday: http://t.co/aD50CMSH
about 2 days ago Thinly traded BioLineRx shares move on hepatitis C deal: The shares of thinly traded BioLineRx (NASDAQ:BLRX) soa... http://t.co/ugbuZgNN
about 2 days ago Orexigen® Announces Agreement From the FDA on a Special Protocol Assessment; Acorda Announces Launch of Generic ... http://t.co/vSt6VrLP
about 2 days ago $CVM up 17% and technically looks like it may head higher.
about 3 days ago $ANAC drops after GlaxoSmithKline (GSK) pauses enrollment for its clinical trials of its urinary tract infection drug. http://t.co/yUUSzkUr

navigation

Free Phone Trade Alerts